Attralus Gets $116M Financing Boost to Develop Imaging Agent

Attralus Gets $116M Financing Boost to Develop Imaging Agent

307455

Attralus Gets $116M Financing Boost to Develop Imaging Agent

Attralus has raised $116 million to support the clinical development of AT-01, its diagnostic imaging agent for systemic amyloidosis, a group of rare conditions that includes familial amyloid polyneuropathy (FAP). Proceeds from the Series B financing will also be used to develop therapeutic agents for different forms of systemic amyloidosis, according to the company. Systemic amyloidosis is an umbrella term for a group of rare disorders characterized by the buildup of abnormal protein deposits, called amyloid,…

You must be logged in to read/download the full post.